- Home
- FTHY vs FLGT Comparison
FTHY vs FLGT Comparison
Compare FTHY & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- FLGT
- Stock Information
- Founded
- FTHY 2020
- FLGT 2011
- Country
- FTHY United States
- FLGT United States
- Employees
- FTHY N/A
- FLGT N/A
- Industry
- FTHY Investment Managers
- FLGT Medical Specialities
- Sector
- FTHY Finance
- FLGT Health Care
- Exchange
- FTHY Nasdaq
- FLGT Nasdaq
- Market Cap
- FTHY 500.1M
- FLGT 587.3M
- IPO Year
- FTHY N/A
- FLGT 2016
- Fundamental
- Price
- FTHY $14.72
- FLGT $18.41
- Analyst Decision
- FTHY
- FLGT Buy
- Analyst Count
- FTHY 0
- FLGT 2
- Target Price
- FTHY N/A
- FLGT $24.00
- AVG Volume (30 Days)
- FTHY 176.7K
- FLGT 237.7K
- Earning Date
- FTHY 01-01-0001
- FLGT 08-01-2025
- Dividend Yield
- FTHY 10.93%
- FLGT N/A
- EPS Growth
- FTHY N/A
- FLGT N/A
- EPS
- FTHY N/A
- FLGT N/A
- Revenue
- FTHY N/A
- FLGT $292,448,000.00
- Revenue This Year
- FTHY N/A
- FLGT $11.79
- Revenue Next Year
- FTHY N/A
- FLGT $10.45
- P/E Ratio
- FTHY N/A
- FLGT N/A
- Revenue Growth
- FTHY N/A
- FLGT 1.71
- 52 Week Low
- FTHY $12.66
- FLGT $14.57
- 52 Week High
- FTHY $14.74
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- FTHY 56.93
- FLGT 41.01
- Support Level
- FTHY $14.62
- FLGT $17.50
- Resistance Level
- FTHY $14.87
- FLGT $19.24
- Average True Range (ATR)
- FTHY 0.11
- FLGT 0.64
- MACD
- FTHY -0.01
- FLGT -0.03
- Stochastic Oscillator
- FTHY 59.46
- FLGT 36.99
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.